Intra Cellular Therapies | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Biogen USD 5.53B 103.8M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Cytokinetics USD 179.67M 69.86M 2024-12
Gilead Sciences USD 12B 279M 2024-12
Halozyme Therapeutics USD 139.1M 30.28M 2024-12
Intra Cellular Therapies USD 205.7M 39.59M 2024-12
J&J USD 50.32B 1.44B 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Prothena USD 48.5M 2.08M 2024-12
RedHill Biopharma USD 21.23M 0 2024-06
Supernus Pharmaceuticals USD 292.4M 889K 2024-12
United Therapeutics USD 738.1M 135.3M 2024-12



Intra Cellular Therapies Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.